Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer

Sponsor
Oslo University Hospital
Study ID
NCT01518621
Phase
PHASE2
Status
Terminated

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Radiation — RADIATION
    Whole brain radiation
  • Radiation plus erlotinib — DRUG
    Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation

Study Details

To determine if erlotinib given orally along with concurrent whole brain irradiation in lung cancer patients with brain metastases improves median overall survival and enhances local control compared to those treated with WBRT alone, without significantly increasing the risk of side effects or lowering quality of life.

Key Dates

First listed
Jan 26, 2012
Start date
May 31, 2012
Status verified
Mar 2019
Primary completion
Dec 10, 2017
Completion
Dec 10, 2018

Study Design

Enrollment
25 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Radiotherapy alone
    Total brain irradiation, 3Gy x10
  • Experimental: Radiation plus erlotinib
    Total brain irradiation, 3Gy x10 plus erlotinib 150 mg q d from radiation day -1 through last day of irradiation

Related Studies